 |
|
Cisplatin Sensitization to Radiotherapy in Stage IV Squamous Cell Carcinoma of the Head and NeckA Follow-up Report
Nancy L. Snyderman, MD;
Stephen J. Wetmore, MD;
James Y. Suen, MD
Arch Otolaryngol Head Neck Surg. 1986;112(11):1147-1150.
Abstract
• Thirty-six patients with stage IV squamous cell carcinoma of the head and neck were treated with cisplatin (15 mg/m2), administered synchronously with high-dose radiation therapy. Of the original 36 patients, 26 are dead of disease. Although previous reports of an 88% response to this regimen were noted, the disease-free intervals in this 36-patient group were short. The interval of time between treatment and death ranged from two to 27 months, with an average survival time of 10.7 months. It appears that although cisplatin potentiation to radiation therapy offers an encouraging clinical response initially, persistent clinical regression of disease is unlikely. Further studies of cisplatin sensitization of radiation therapy vs radiation therapy alone and chemotherapy alone need to be performed before this regimen can be considered strong enough to stand on its own merits.
(Arch Otolaryngol Head Neck Surg 1986;112:1147-1150)
Author Affiliations
From the Department of Otolaryngology, University of Arkansas for Medical Sciences, Little Rock.
Footnotes
Accepted for publication June 10, 1986.
Read before the American Society for Head and Neck Surgery, Palm Beach, Fla, May 8, 1986.
Reprint requests to Department of Otolaryngology, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR 72205 (Dr Snyderman).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Carboplatin-Radiation Interaction in Squamous Cell Carcinoma Cell Lines
Pekkola-Heino et al.
Arch Otolaryngol Head Neck Surg 1992;118:1312-1315.
ABSTRACT
|
